

April 9, 2026

To All Concerned Parties,

Company: Asahi Intecc Co., Ltd.
Representative: Kenji Miyata, President & CEO
(Securities code: 7747, Prime of Tokyo Stock Exchange and Premier of
Nagoya Stock Exchange)
Contact:
Mizuho Ito, Member of Board & CFO, General Manager of Administration
(TEL. +81-561-48-5551)

Notice Regarding Conclusion of an Exclusive Distribution Agreement for Embolization Agents in the Japanese Market

1. Overview of this Agreement

Asahi Intecc announces that its board of directors resolved today to enter into an exclusive distribution agreement in Japan for the embolization agent “Nexsphere-F™,” developed and manufactured by NEXTBIOMEDICAL CO., LTD. (hereinafter “Nextbio”) of South Korea.

Although “Nexsphere-F™” is currently not approved for pharmaceutical use in Japan, based on this agreement, the Company plans to seek inclusion in the national health insurance coverage after obtaining regulatory approval and to begin direct sales to hospitals and other facilities through its wholly-owned consolidated subsidiary, Asahi Intecc J-sales, Inc. The term of this agreement is set for five years following inclusion in the national health insurance coverage in Japan, with annual renewals anticipated thereafter.

The subject product, “Nexsphere-F,” is a temporary embolization agent (beads) with a proven track record of use in TAME (Transcatheter Arterial Micro-Embolization) treatments overseas.

Leveraging its established relationships with physicians, product development capabilities, and sales network, the Company will advance initiatives to promote this product while also anticipating synergies with our Group’s related products (such as abdominal microcatheters and abdominal guidewires).

Through this agreement with Nextbio, the Company will expand the potential of TAME as a new treatment option for chronic pain patients and contribute to improving their quality of life (QOL).

Nexsphere-F is already being sold in the Company’s direct sales regions in Europe (France, Germany, and Italy), and activities to promote this treatment are underway.

Knowledge regarding the clinical use of “Nexsphere-F” has been accumulated through academic presentations and literature to date. Based on this track record, the Company expects this product to provide new value in the Japanese market as well.

*: TAME treatment: Transcatheter Arterial Micro-Embolization

This treatment involves inserting a catheter into an artery through a blood vessel in the wrist, elbow, or groin to deliver an embolization agent to the abnormal blood vessel causing chronic pain.

2. About NEXTBIOMEDICAL CO., LTD.

NEXTBIOMEDICAL CO., LTD. is a medical device company headquartered in South Korea that develops and manufactures innovative therapeutic solutions, such as the endoscopic hemostatic agent "Nexpowder™" and the embolization agent "Nexsphere™" and "Nexsphere-F™."

Company name	NEXTBIOMEDICAL CO., LTD..
Location	Incheon, South Korea
Name and title of representative	Don Haeng Lee, CEO
Establishment	August 2014
Listing market	KOSDAQ
Business area	Development and manufacturing of medical devices such as endoscopic hemostatic agents and embolization agents

3. Date

Date of Board Resolution: April 9, 2026

Date of Contract Execution: April 9, 2026

4. Future Outlook

This matter will have no impact on the Group's consolidated financial results for the current fiscal year.